Effects of Transcranial Direct Current Stimulation in Refractory Chronic Migraine and Medication-overuse Headache
Not Applicable
- Conditions
- Chronic MigraineMedication Overuse Headache
- Interventions
- Device: Anodal transcranial direct current stimulationDevice: Sham transcranial direct current stimulation
- Registration Number
- NCT01752439
- Lead Sponsor
- Dr Armando Perrotta, MD, PhD
- Brief Summary
The purpose of the study is to evaluate the efficacy of the transcranial direct current stimulation of the primary motor cortex (M1) in patients affected by refractory chronic migraine (coded as 1.5.1 in the international headache classification 2nd edition, 2004) and medication-overuse headache (coded as 8.1) with migraine as primary headache.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Chronic MIgraine or Medication Overuse Headache according to the diagnostic criteria set out in the 2nd edition of the International Classification of Headache Disorders refractory to treatment according to the Refractory Headache Special Interest Section of the American Headache Society (Schulman et al., 2008)
Exclusion Criteria
- Other primary or secondary headaches.
- Any serious systemic or neurological disease or psychiatric disorder.
- Pregnancy or breastfeeding
- Previous or current use of other or similar devices for pain control
- Heart conduction and rhythm disorders
- Cranial surgery
- Other pain conditions, accordingly with current guidelines
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Anodal transcranial direct current stimulation Anodal transcranial direct current stimulation Anodal transcranial direct current stimulation Sham transcranial direct current stimulation Sham transcranial direct current stimulation Sham transcranial direct current stimulation
- Primary Outcome Measures
Name Time Method Change in headache days per months at 30, 60 and 90 days after the treatment Change in drugs intake per months at 30, 60 and 90 days after treatment
- Secondary Outcome Measures
Name Time Method Change in mean pain intensity score per months at 30, 60 and 90 days after treatment